MedTrace Logo

A Trial Evaluating TG4050 in Ovarian Carcinoma.

NCT03839524 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-11-14

Study results available
· View outcomes & findings →

Summary

This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.

Conditions

Interventions

DRUG

TG4050

Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.

Sponsors & Collaborators

  • Transgene

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2024-10-08
Completion
2024-10-08
FDA Drug
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03839524 on ClinicalTrials.gov